What Researchers Did
Researchers retrospectively analyzed the efficacy and safety of hyperbaric oxygen therapy (HBOT) for chronic antibiotic-refractory pouchitis (CARP) and other inflammatory pouch conditions in 46 adult patients.
What They Found
They found a significant reduction in the mean Pouchitis Disease Activity Index (mPDAI) symptom subscore from 3.19 to 1.91 after HBOT (P < 0.05). Endoscopic subscores also significantly improved across the afferent limb, pouch body, and cuff (all P < 0.001 to P = 0.006), with transient side effects like ear barotrauma and myopic vision changes occurring in 5 patients (10.9%) each.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or patients.
Study Limitations
As a retrospective case series, this study is limited by its design, which inherently lacks a control group and may be subject to selection bias.